ARS Pharmaceuticals (SPRY) Current Deferred Revenue (2020 - 2026)
ARS Pharmaceuticals (SPRY) reported Current Deferred Revenue of $757000.0 for Q1 2026, up 40.19% on a YoY basis from $540000.0 in Q1 2025, and up 24.3% sequentially from $609000.0 in Q4 2025.
ARS Pharmaceuticals (SPRY) Current Deferred Revenue (2020 - 2026) Analysis & Trends
ARS Pharmaceuticals (SPRY) has 7 years of Current Deferred Revenue data on file, last reported at $757000.0 in Q1 2026.
- For the quarter ending Q1 2026, Current Deferred Revenue rose 40.19% year-over-year to $757000.0; the trailing twelve-month figure through Mar 2026 stood at $757000.0 (up 40.19% YoY), and the FY2025 full-year result was $609000.0, up 9.34% from the prior year.
- Current Deferred Revenue improved to $757000.0 in Q1 2026, from $609000.0 in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $3.1 million in Q4 2023 to a low of $10000.0 in Q1 2023.
- A 5-year average of $792000.0 and a median of $557000.0 in 2024 frame the typical range for Current Deferred Revenue.
- Across the five-year window, Current Deferred Revenue jumped 995.41% in 2023 and sank 82.03% in 2024, its largest moves.
- Tracing SPRY's Current Deferred Revenue over 5 years: stood at $283000.0 in 2022, then jumped by 995.41% to $3.1 million in 2023, then slumped by 82.03% to $557000.0 in 2024, then increased by 9.34% to $609000.0 in 2025, then gained by 24.3% to $757000.0 in 2026.
- Business Quant data shows SPRY's Current Deferred Revenue at $757000.0 in Q1 2026, $609000.0 in Q4 2025, and $526000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | ARS Pharmaceuticals | 595.78 Mn | 394.81 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 757,000.00 |
| Dec 31, 2025 | 609,000.00 |
| Sep 30, 2025 | 526,000.00 |
| Jun 30, 2025 | 746,000.00 |
| Mar 31, 2025 | 540,000.00 |
| Dec 31, 2024 | 557,000.00 |
| Dec 31, 2023 | 3.10 Mn |
| Mar 31, 2023 | 10,000.00 |
| Dec 31, 2022 | 283,000.00 |
| Dec 31, 2021 | 1.46 Mn |
| Sep 30, 2020 | 3.10 Mn |